João Costa1, Michael Swash, Mamede de Carvalho. 1. Neuromuscular Unit, Institute of Molecular Medicine, Faculty of Medicine, University of Lisbon, 1649028 Lisbon, Portugal. joaoncosta@sapo.pt
Abstract
OBJECTIVE: To estimate the potential diagnostic added value of the Awaji criteria for diagnosis of a myotrophiclateral sclerosis (ALS), which have been compared with the previously accepted gold standard the revised El Escorial criteria in several studies. DATA SOURCES: MEDLINE and Web of Science (until October2011). STUDY SELECTION: We searched for studies testing the diagnostic accuracy of the Awaji criteria vs the revised El Escorial criteria in patients referred with suspected ALS. DATA EXTRACTION: Evaluation and data extraction of identified studies were done independently. The Quality Assessment of Diagnostic Accuracy Studies list was used to assess study quality. We determined the proportion of patients classified as having probable/definite ALS and derived indices of diagnostic performance(sensitivity, specificity, and diagnostic odds ratio). Quantitative data synthesis was accomplished through random-effects meta-analysis, and heterogeneity was assessed with the I2 test. DATA SYNTHESIS: Eight studies were included (3 prospective and 5 retrospective) enrolling 1187 patients. Application of Awaji criteria led to a 23% (95% CI, 12% to 33%; I2=84%) increase in the proportion of patients classified as having probable/definite ALS. Diagnostic performance of the Awaji criteria was higher than the revised El Escorial criteria (pooled sensitivity: 81.1% [95%CI, 72.2% to 90.0%; I2=91%] vs 62.2% [95% CI, 49.4%to 75.1%; I2=93%]; pooled diagnostic odds ratio, 35.8[95% CI, 15.2 to 84.7; I2=3%] vs 8.7 [95% CI, 2.2 to 35.6;I2=50%]). Diagnostic accuracy of Awaji criteria was higher in bulbar- than in limb-onset cases. CONCLUSION: The Awaji criteria have a significant clinical impact allowing earlier diagnosis and clinical trial entry in ALS.
OBJECTIVE: To estimate the potential diagnostic added value of the Awaji criteria for diagnosis of a myotrophiclateral sclerosis (ALS), which have been compared with the previously accepted gold standard the revised El Escorial criteria in several studies. DATA SOURCES: MEDLINE and Web of Science (until October2011). STUDY SELECTION: We searched for studies testing the diagnostic accuracy of the Awaji criteria vs the revised El Escorial criteria in patients referred with suspected ALS. DATA EXTRACTION: Evaluation and data extraction of identified studies were done independently. The Quality Assessment of Diagnostic Accuracy Studies list was used to assess study quality. We determined the proportion of patients classified as having probable/definite ALS and derived indices of diagnostic performance(sensitivity, specificity, and diagnostic odds ratio). Quantitative data synthesis was accomplished through random-effects meta-analysis, and heterogeneity was assessed with the I2 test. DATA SYNTHESIS: Eight studies were included (3 prospective and 5 retrospective) enrolling 1187 patients. Application of Awaji criteria led to a 23% (95% CI, 12% to 33%; I2=84%) increase in the proportion of patients classified as having probable/definite ALS. Diagnostic performance of the Awaji criteria was higher than the revised El Escorial criteria (pooled sensitivity: 81.1% [95%CI, 72.2% to 90.0%; I2=91%] vs 62.2% [95% CI, 49.4%to 75.1%; I2=93%]; pooled diagnostic odds ratio, 35.8[95% CI, 15.2 to 84.7; I2=3%] vs 8.7 [95% CI, 2.2 to 35.6;I2=50%]). Diagnostic accuracy of Awaji criteria was higher in bulbar- than in limb-onset cases. CONCLUSION: The Awaji criteria have a significant clinical impact allowing earlier diagnosis and clinical trial entry in ALS.
Authors: Angeline S Andrew; Celia Y Chen; Tracie A Caller; Rup Tandan; Patricia L Henegan; Brian P Jackson; Brenda P Hall; Walter G Bradley; Elijah W Stommel Journal: Muscle Nerve Date: 2018-01-04 Impact factor: 3.217
Authors: Thomas Kuczmarski; Elijah W Stommel; Kristen Riley; Rup Tandan; Vinay Chaudhry; Lora Clawson; Tracie A Caller; Patricia L Henegan; Dominic N Facciponte; Walter G Bradley; Angeline S Andrew Journal: J Neurol Date: 2017-07-15 Impact factor: 4.849
Authors: Vincent Picher-Martel; Paul N Valdmanis; Peter V Gould; Jean-Pierre Julien; Nicolas Dupré Journal: Acta Neuropathol Commun Date: 2016-07-11 Impact factor: 7.801
Authors: Donatienne Van Weehaeghe; Martijn Devrome; Michel Koole; Koen Van Laere; Georg Schramm; Joke De Vocht; Wies Deckers; Kristof Baete; Philip Van Damme Journal: Eur J Nucl Med Mol Imaging Date: 2020-04-20 Impact factor: 9.236
Authors: Angeline S Andrew; Erik P Pioro; Meifang Li; Xun Shi; Jiang Gui; Elijah W Stommel; Tanya H Butt; Daniel Peipert; Patricia Henegan; Maeve Tischbein; Pamela Cazzolli; John Novak; Adam Quick; K Doug Pugar; Komal Sawlani; Bashar Katirji; Todd A Hayes; D Kevin Horton; Paul Mehta; Walter G Bradley Journal: Neuroepidemiology Date: 2021-04-26 Impact factor: 3.282